BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19846344)

  • 1. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.
    Salemi S; Picchianti-Diamanti A; Germano V; Donatelli I; Di Martino A; Facchini M; Nisini R; Biselli R; Ferlito C; Podestà E; Cappella A; Milanetti F; Rossi F; Amodeo R; Tabacco F; Di Rosa R; Laganà B; D Amelio R
    Clin Immunol; 2010 Feb; 134(2):113-20. PubMed ID: 19846344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O
    Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
    Del Porto F; Laganà B; Biselli R; Donatelli I; Campitelli L; Nisini R; Cardelli P; Rossi F; D'Amelio R
    Vaccine; 2006 Apr; 24(16):3217-23. PubMed ID: 16466833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
    Gelinck LB; van der Bijl AE; Beyer WE; Visser LG; Huizinga TW; van Hogezand RA; Rimmelzwaan GF; Kroon FP
    Ann Rheum Dis; 2008 May; 67(5):713-6. PubMed ID: 17965123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
    Kobie JJ; Zheng B; Bryk P; Barnes M; Ritchlin CT; Tabechian DA; Anandarajah AP; Looney RJ; Thiele RG; Anolik JH; Coca A; Wei C; Rosenberg AF; Feng C; Treanor JJ; Lee FE; Sanz I
    Arthritis Res Ther; 2011; 13(6):R209. PubMed ID: 22177419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.
    Fomin I; Caspi D; Levy V; Varsano N; Shalev Y; Paran D; Levartovsky D; Litinsky I; Kaufman I; Wigler I; Mendelson E; Elkayam O
    Ann Rheum Dis; 2006 Feb; 65(2):191-4. PubMed ID: 16014674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.
    Kaine JL; Kivitz AJ; Birbara C; Luo AY
    J Rheumatol; 2007 Feb; 34(2):272-9. PubMed ID: 17304653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
    van Assen S; Holvast A; Benne CA; Posthumus MD; van Leeuwen MA; Voskuyl AE; Blom M; Risselada AP; de Haan A; Westra J; Kallenberg CG; Bijl M
    Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
    Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
    J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
    Baldwin HM; Ito-Ihara T; Isaacs JD; Hilkens CM
    Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC; Guedes LK; Moraes JC; Saad CG; Aikawa NE; Calich AL; França IL; Carvalho JF; Sampaio-Barros PD; Goncalves CR; Borba EF; Timenetsky Mdo C; Precioso AR; Duarte A; Bonfa E; Laurindo IM
    Ann Rheum Dis; 2011 Dec; 70(12):2144-7. PubMed ID: 21859696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.